<DOC>
	<DOCNO>NCT02990806</DOCNO>
	<brief_summary>The purpose study demonstrate similarity NI-071 ( propose biosimilar infliximab ) US REMICADE® ( reference product ) term safety efficacy patient rheumatoid arthritis ( RA ) adequately respond methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Phase 3 Study NI-071 Patients With Rheumatoid Arthritis ( RADIANCE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients diagnosis rheumatoid arthritis ( RA ) define 2010 ACR European League Against Rheumatism ( EULAR ) classification criterion Patients active RA , confirm follow criterion : ≥6 swollen joint ≥6 tender joint screen baseline ( 28joint count ) Creactive protein ( CRP ) ≥0.7 mg/dL ( ≥7.0 mg/L ) screening Patients take methotrexate ( MTX ) ( oral parenteral ) least 3 month prior screen stable dose 10 25 mg/week least 8 week . Concomitant folic/folinic acid dose least 5 mg/week take study ; patient start treatment folic/folinic acid screen already receive . If patient currently take nonsteroidal antiinflammatory drug ( NSAIDs ) , patient must stable dose least 4 week prior screen study . Patients ≥18 ≤75 year age screen Patients rat Class IV accord 1991 ACR revise criterion classification global functional status RA Patients receive diseasemodifying anti rheumatic drug ( DMARDs ) , MTX , within period prior screen short washout period appropriate pharmacodynamic profile specific drug Patients receive immunosuppressive drug within 4 week prior screen . Patients stable dose oral corticosteroid ( ≤10 mg/day prednisone equivalent ) ≥4 week prior screen permit . Patients receive intraarticular , intramuscular , intravenous , epidural injection corticosteroid within 4 week prior screen Patients receive intraarticular sodium hyaluronate injection within 4 week prior screen Patients receive surgical therapy RA synovectomy arthroplasty within 6 month prior screen Patients receive arthrocentesis within 4 week prior screen Patients prior treatment infliximab Patients prior treatment &gt; 1 biological drug &gt; 1 protein kinase inhibitor RA either part clinical management clinical study Patients prior treatment tumor necrosis factor alpha ( TNFα ) inhibitor RA lack efficacy per clinical judgment ( primary failure ) . Patients discontinue TNFα inhibitor RA ( infliximab ) reason lack efficacy allow . Presence chronic acute infection screening , include positive result active tuberculosis ( TB ) Patients acute infection require parenteral antibiotic within 4 week study dose require oral/topical antibiotic within 2 week study dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>